Light Therapy for Fatigue and Daytime Sleepiness in Multiple Sclerosis
Fatigue and excessive daytime sleepiness are common complaints in individuals living with multiple sclerosis (MS). Fatigue and excessive daytime sleepiness are associated with the emergence and exacerbation of cognitive, motor and mood disturbances and over time lead to impaired rehabilitation outcomes, a decline in the capacity to perform daily activities and reduced quality of life. […]
SARS-CoV-2 antibody after COVID-19 vaccination in patients with multiple sclerosis
COVID-19 vaccines are now being rolled out. Many people living with MS are treated with drugs that affect their immune system, and there is not a lot of specific data relating to the administration of the COVID-19 vaccines to a person with MS who is treated for their disease. This is a multi-center study to […]
The QUEST initiative: QUality of life Evaluation STudy: Assessing Health Related Quality of Life in patients receiving medicinal cannabis
You are invited to take part in a research study exploring quality of life in patients accessing medicinal cannabis. People accessing medicinal cannabis may have a range of conditions and symptoms that impact their quality of life. We would like to know how these conditions and symptoms impact quality of life and if this changes […]
Crisis resilience in persons with multiple sclerosis (C-RIMS)
Community disasters, such as floods and bushfires, affect many towns and communities. The crisis can last for several months, with effects being felt for much longer. Prior preparation for a crisis can help with feelings of coping and maintaining your health during this time. There are a number of tools available to help you prepare […]
Autologous Haematopoietic Stem Cell Transplantation for highly active treatment resistant multiple sclerosis
We propose to study the benefits and risks of Autologous Haematopoetic Stem Cell Transplant (AHSCT) in people who have an aggressive form of MS not controlled by conventional treatment. Participants will have AHSCT at The Alfred hospital, and they will be closely monitored for 5 years post the transplant to ensure their safety, and also […]
A Phase II observational study of Haematopoietic Stem Cell Transplantation for highly active, treatment resistant MS
This trial is testing whether an autologous (self) haematopoietic stem cell transplant (AHSCT) for highly active, treatment resistant multiple sclerosis reduces MS disease activity over 5 years. The treatment involves: treatment, collection and freezing of stem cells from the patient’s blood; chemotherapy (BEAM-ATG) to destroy the immune system; reinfusion of the patient’s own stem cells. […]
Australian MS Longitudinal Study
The Australian MS Longitudinal Study (AMSLS) is not a clinical trial. It is a survey-based study of life issues, designed to more fully understand the impact of MS, including the individual and overall community impacts. The data from the AMSLS provides a regularly updated, evidence base for a number of stakeholders including health professionals, scientific […]